Deutetrabenazine (Austedo®) for tardive dyskinesia

On August 30, 2017, the US FDA approved deutetrabenazine (brand name Austedo®) for the treatment of tardive dyskinesia in adults. Deutetrabenazine is already FDA-approved for the treatment of chorea associated with Huntington’s disease. This is the second medication ever approved the FDA for the treatment of tardive dyskinesia. The first was valbenazine (Ingrezza®), which was approved in…